484 related articles for article (PubMed ID: 19019623)
1. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
Zhu BQ; Ju SW; Shu YQ
Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
[TBL] [Abstract][Full Text] [Related]
2. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
Lu PH; Negrin RS
J Immunol; 1994 Aug; 153(4):1687-96. PubMed ID: 7519209
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma.
Kim HM; Lim J; Yoon YD; Ahn JM; Kang JS; Lee K; Park SK; Jeong YJ; Kim JM; Han G; Yang KH; Kim YJ; Kim Y; Han SB
Int Immunopharmacol; 2007 Dec; 7(13):1793-801. PubMed ID: 17996690
[TBL] [Abstract][Full Text] [Related]
4. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
6. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
7. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
[TBL] [Abstract][Full Text] [Related]
8. Possibility of adoptive immunotherapy with peripheral blood-derived CD3⁻CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity.
Doskali M; Tanaka Y; Ohira M; Ishiyama K; Tashiro H; Chayama K; Ohdan H
J Immunother; 2011 Mar; 34(2):129-38. PubMed ID: 21304407
[TBL] [Abstract][Full Text] [Related]
9. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene.
Finke S; Trojaneck B; Lefterova P; Csipai M; Wagner E; Kircheis R; Neubauer A; Huhn D; Wittig B; Schmidt-Wolf IG
Gene Ther; 1998 Jan; 5(1):31-9. PubMed ID: 9536262
[TBL] [Abstract][Full Text] [Related]
10. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers.
Sangiolo D; Martinuzzi E; Todorovic M; Vitaggio K; Vallario A; Jordaney N; Carnevale-Schianca F; Capaldi A; Geuna M; Casorzo L; Nash RA; Aglietta M; Cignetti A
Int Immunol; 2008 Jul; 20(7):841-8. PubMed ID: 18469328
[TBL] [Abstract][Full Text] [Related]
11. Activation-induced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro.
Kelly-Rogers J; Madrigal-Estebas L; O'Connor T; Doherty DG
Hum Immunol; 2006 Nov; 67(11):863-73. PubMed ID: 17145366
[TBL] [Abstract][Full Text] [Related]
12. Transgene-enforced co-stimulation of CD4+ T cells leads to enhanced and sustained anti-tumor effector functioning.
Chang L; Chang WC; McNamara G; Aguilar B; Ostberg JR; Jensen MC
Cytotherapy; 2007; 9(8):771-84. PubMed ID: 17917884
[TBL] [Abstract][Full Text] [Related]
13. In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads.
Teschner D; Wenzel G; Distler E; Schnürer E; Theobald M; Neurauter AA; Schjetne K; Herr W
Scand J Immunol; 2011 Aug; 74(2):155-64. PubMed ID: 21517928
[TBL] [Abstract][Full Text] [Related]
14. [Identification of immunological effector cells after autologous cytokine-induced killer cells treatment and its clinical implication in hepatocellular carcinoma patients].
Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Liu JC; Fan ZP; Li HW; Mu JS; Wang FS
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2049-53. PubMed ID: 14703414
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.
Schmidt-Wolf IG; Lefterova P; Mehta BA; Fernandez LP; Huhn D; Blume KG; Weissman IL; Negrin RS
Exp Hematol; 1993 Dec; 21(13):1673-9. PubMed ID: 7694868
[TBL] [Abstract][Full Text] [Related]
16. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.
Franceschetti M; Pievani A; Borleri G; Vago L; Fleischhauer K; Golay J; Introna M
Exp Hematol; 2009 May; 37(5):616-628.e2. PubMed ID: 19375652
[TBL] [Abstract][Full Text] [Related]
17. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.
Wang Y; Bo J; Dai HR; Lu XC; Lv HY; Yang B; Wang T; Han WD
Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo.
Ferran C; Dautry F; Mérite S; Sheehan K; Schreiber R; Grau G; Bach JF; Chatenoud L
J Clin Invest; 1994 May; 93(5):2189-96. PubMed ID: 8182150
[TBL] [Abstract][Full Text] [Related]
19. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model.
Kim HM; Kang JS; Lim J; Kim JY; Kim YJ; Lee SJ; Song S; Hong JT; Kim Y; Han SB
Arch Pharm Res; 2009 May; 32(5):781-7. PubMed ID: 19471894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]